Patrick Cambier, MD
Interventional Cardiology · Trinity, FLNPI 1508828591
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $718,162 of the $900,660 with a category attached, or 79.7%. 37 manufacturers reported payments, led by AstraZeneca at 36.7% of the total. Among interventional cardiology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,249 payments — averaging $721.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$331K
- Novo Nordisk$301K
- Merck$101K
- E.r. Squibb & Sons, L.L.C.$77K
- Pfizer$61K
- Angiodynamics, Inc.$22K
- plus $8K from 31 others
Across 27 payments — averaging $5899.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$153K
- Amgen$6K
- Bard Peripheral Vascular, Inc.$50
What the payments were for
- Consulting fees$74,5558%
- Speaking & faculty fees$718,16280%
- Travel & lodging$60,4347%
- Food & beverage$25,3063%
- Education$2850%
- Other$21,9172%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 388 | $330,665 |
| Novo Nordisk | 189 | $300,536 |
| Merck | 130 | $100,989 |
| E.r. Squibb & Sons, L.L.C. | 85 | $77,035 |
| Pfizer | 101 | $60,996 |
| Angiodynamics, Inc. | 8 | $22,011 |
| Medtronic(2 entities) | 46 | $1,232 |
| Teleflex LLC | 2 | $1,210 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 56 | $838 |
| Amgen | 41 | $668 |
| Novartis | 35 | $547 |
| Cardiovascular Systems Inc. | 47 | $465 |
| Abbott | 10 | $401 |
| Johnson & Johnson | 17 | $319 |
| Alnylam Pharmaceuticals Inc. | 11 | $270 |
| Boston Scientific | 14 | $255 |
| Corindus Inc. | 3 | $240 |
| Astellas Pharma US Inc | 4 | $230 |
| Shockwave Medical, Inc | 2 | $224 |
| Sanofi-aventis U.S. LLC | 12 | $223 |
| Amarin Pharma, Inc. | 9 | $192 |
| Boehringer Ingelheim | 9 | $180 |
| Abiomed | 4 | $163 |
| Siemens Medical Solutions USA, Inc. | 2 | $159 |
| Bayer | 2 | $87 |
| Lilly USA, LLC | 4 | $76 |
| Scpharmaceuticals Inc. | 2 | $68 |
| Edwards Lifesciences | 1 | $63 |
| Esperion Therapeutics, Inc. | 4 | $56 |
| Lexicon Pharmaceuticals, Inc. | 3 | $54 |
| Inari Medical, Inc. | 1 | $52 |
| Bridgebio Pharma, Inc. | 2 | $44 |
| United Therapeutics Corporation | 1 | $31 |
| Biotronik Inc. | 1 | $28 |
| Kestra Medical Technology Services, Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Penumbra, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$181,865
- Ozempic$169,742
- VERQUVO$151,852
- ELIQUIS$103,389
- BRILINTA$64,602
- BREZTRI$27,488
- Auryon Laser System 100-120 Vac$21,917
- RYBELSUS$16,420
- VYNDAQEL$15,950
- AIRSUPRA$1,540
- MANTA$1,200
- CorPath GRX$230
- MitraClip$137
- Vascular Lithotripsy$131
- Mitra Clip system$128
- LINQ II$125
- Repatha$121
How this compares
$900,660 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 516 | $530,171 |
| FarxigaDapagliflozin Propanediol | 377 | $377,313 |
| EntrestoSacubitril/Valsartan | 329 | $305,009 |
| OzempicSemaglutide | 177 | $189,868 |
| Repatha SureclickEvolocumab | 188 | $138,755 |
| XareltoRivaroxaban | 64 | $71,212 |
| BrilintaTicagrelor | 95 | $69,212 |
| MultaqDronedarone Hcl | 49 | $55,605 |
| JardianceEmpagliflozin | 37 | $45,917 |
| VerquvoVericiguat | 25 | $16,707 |
| Repatha SyringeEvolocumab | 21 | $15,937 |
| Candesartan Cilexetil | 189 | $13,493 |
| Rosuvastatin Calcium | 873 | $10,200 |
| Metoprolol Succinate | 724 | $9,121 |
| VascepaIcosapent Ethyl | 22 | $7,840 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $60,996 | $530,171516 claims |
| AstraZenecaFarxiga, Brilinta | $330,665 | $446,526472 claims |
| NovartisEntresto | $547 | $305,009329 claims |
| Novo NordiskOzempic | $300,536 | $189,868177 claims |
| Johnson & JohnsonXarelto | $319 | $71,21264 claims |
| Sanofi-aventis U.S. LLCMultaq | $223 | $55,60549 claims |
| Boehringer IngelheimJardiance | $180 | $45,91737 claims |
| MerckVerquvo | $100,989 | $16,70725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Trinity
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
- Douglas EbersoleLakeland$373K
- Amit SharmaMerritt Island$341K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.